非小细胞肺癌新辅助免疫治疗研究进展  

Advance in Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer

作　　者：马天宇 周世杰[1] 程序[1] 王宇轩 刘志东[1] MA Tianyu;ZHOU Shijie;CHENG Xu;WANG Yuxuan;LIU Zhidong(Beijing Chest Hospital Affiliated to Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute,Beijing 101149,China)

机构地区：[1]首都医科大学附属北京胸科医院/北京结核病胸部肿瘤研究所,北京101149

出　　处：《中国肿瘤》2023年第10期780-788,共9页China Cancer

摘　　要：肺癌是全球最常见的癌症之一,也是癌症相关死亡最主要原因,其中非小细胞肺癌(NSCLC)约占肺癌人群的85%。免疫检查点抑制剂(ICI)的出现,使得NSCLC的治疗方案发生显著变化。众多新辅助免疫治疗相关临床试验的出现,标志着可切除NSCLC进入了免疫治疗的时代。然而,随着免疫方案研究的不断深入,新辅助免疫治疗仍然面临着诸多问题期待予以解决。全文围绕NSCLC新辅助免疫治疗的相关研究与进展进行综述。Lung cancer is one of the most common cancers in the world,and it is also the main cause of cancer related deaths,and non-small cell lung cancer(NSCLC)accounts for about 85%of the lung cancers.Due to the development of immune checkpoint inhibitor(ICI)therapy,the treatment regimen of NSCLC has changed significantly.A large number of clinical trials indicated that resectable NSCLC has entered the era of immunotherapy.However,the neoadjuvant immunotherapy is still facing some problems that are expected to be solved in future study.This paper reviews the research progress of neoadjuvant immunotherapy for NSCLC.

关 键 词：非小细胞肺癌 免疫检查点抑制剂 新辅助治疗 生物标志物 

分 类 号：R734.2[医药卫生—肿瘤]